Manabe Shun, Banno Mayuko, Nakano Marie, Fujii Teruhiro, Fujiwara Michio, Kita Yasuhiko, Nitta Kosaku, Hatano Michiyasu
Department of Nephrology, Yokohama Rosai Hospital, Yokohama, Japan.
Department of Rheumatology, Yokohama Rosai Hospital, Yokohama, Japan.
Case Rep Nephrol Dial. 2014 Oct 29;5(1):30-8. doi: 10.1159/000368826. eCollection 2015 Jan-Apr.
Bucillamine is a disease-modifying antirheumatic drug that is structurally similar to D-penicillamine. The major renal side effect of bucillamine and D-penicillamine is proteinuria caused by membranous nephropathy (MN). In addition to MN, combined crescent formation has been occasionally reported in D-penicillamine-induced MN, while crescent formation has been rarely reported in bucillamine-treated cases. Here, we describe a 76-year-old female who presented with nephrotic syndrome and rapidly progressive glomerulonephritis. She was receiving bucillamine as initial treatment for recently diagnosed rheumatoid arthritis, and renal biopsy showed MN with crescent formation. To the best of our knowledge, this is the first report of bucillamine-induced MN with crescent formation in the English literature.
青霉胺是一种改善病情的抗风湿药物，其结构与D-青霉胺相似。青霉胺和D-青霉胺的主要肾脏副作用是膜性肾病（MN）引起的蛋白尿。除MN外，D-青霉胺诱导的MN偶尔会合并新月体形成，而在接受青霉胺治疗的病例中，新月体形成很少见。在此，我们描述了一名76岁女性，她表现为肾病综合征和快速进展性肾小球肾炎。她因最近诊断出的类风湿关节炎正在接受青霉胺作为初始治疗，肾活检显示为伴有新月体形成的MN。据我们所知，这是英文文献中首例关于青霉胺诱导的伴有新月体形成的MN的报告。
